Recruiting
Phase 2

Oral Supplementation

Sponsor:

McGill University Health Centre/Research Institute of the McGill University Health Centre

Code:

NCT06324214

Conditions

Copd

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

Urolithin A (Mitopure)

Placebo

Study Details

Brief summary:

Chronic obstructive pulmonary disease (COPD) is a very common and chronic lung condition and is a leading cause of morbidity and death. These patients have persistent breathlessness and exercise intolerance, affecting their ability to carry out routine daily tasks. Standard COPD treatments include medicines/puffers as well as participation in a Pulmonary Rehabilitation (PR) program. PR programs are delivered by a diverse team of healthcare experts in exercise and nutrition. It is possible that an emerging nutritional oral supplement could target the muscular dysfunction seen in patients with COPD in part by promoting better working mitochondria, the energy 'engine' of muscle. A series of recently published studies in sedentary adults and in older adults have demonstrated the safety, tolerability, and potential clinical effectiveness of this supplement.

In this regard, the investigators plan to lead a large randomized controlled trial (RCT) to test whether oral supplementation in patients with COPD who are also participating in a standard PR program will improve overall exercise performance. The investigators will also test muscle strength, cognition, body composition, and other clinically important outcomes such as quality of life. Lastly, the investigators will use muscle tissue from a subgroup of volunteers to investigate the effect on muscle/mitochondrial structure/function.

The focus is actually the critical 'first step' before the larger RCT: a pilot and feasibility study on a smaller number of participants with COPD, as an important proof-of-concept that the larger study can, and should, be conducted.

Conditions

Copd

Study ID

NCT06324214

Start date

Mar 11, 2024

Status verified date

Mar, 2024

Completion date

May 31, 2025

Anticipated

Primary completion date

Mar 4, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Males and females, aged >40, former smokers with ≥10 pack-year smoking history
2. Post-bronchodilator forced expiratory volume at one second (FEV1) / forced vital capacity (FVC) ratio < 0.7, with FEV1 < 80% (moderate, Global Initiative for Chronic Obstructive Lung Disease '(GOLD) 2') FEV1 < 50% (severe, 'GOLD 3') or FEV1 < 30% (very severe, 'GOLD 4') COPD
3. Baseline 6MWD of ≥50m
4. Prior receipt of at least 2 doses of the Coronavirus Disease of 2019 (COVID-19) vaccine

Exclusion Criteria:

1. Inability to participate in a standard PR program
2. Severe/unstable cardiac disease, neurological or orthopedic conditions which could hinder exercise performance
3. Inability to provide consent due to language or cognitive barrier
4. Previous PR participation in the last 12 months, or in a study involving an exercise program in the last 6 months
5. Experienced an exacerbation of COPD (ECOPD) within the prior 4 weeks
6. Long-term oxygen therapy use, or maintenance oral corticosteroid use
7. Presence of pacemaker or implantable cardioverter defibrillator (ICD) (unless participant opts out of bioelectrical impedance assay)
8. Unwilling to agree to refrain from using, or are found to be using, the following supplementary antioxidant vitamins from 7 days prior to dosing and throughout the treatment period: Coenzyme Q10, resveratrol, and L-carnitine
9. Unwilling to agree to refrain from using, or are found to be using, the following dietary restrictions from 7 days prior to dosing and throughout the treatment period: pomegranate juice, walnuts, pecans, strawberries, raspberries, and blackberries
10. Allergy to lecithin, to soy or to sunflower
11. Pregnant, breastfeeding or planning to become pregnant
12. Use of anticoagulant or presence of a clotting disorder (if participating in muscle biopsy subgroup)
13. Allergy to anesthetics such as xylocaine and lidocaine (if participating in muscle biopsy subgroup)
14. Chronic myalgia, fibromyalgia or conditions characterized by regular muscle pain (if participating in muscle biopsy subgroup)
15. Metal fixation plates or screws in the legs from a previous surgery (if participating in muscle biopsy subgroup)

Study Design

Enrollment

10 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

placebo comparator: Placebo Group

Participants will participate in a standard PR program and will receive placebo.

active comparator: Intervention (Urolithin A: Mitopure) Group

Participants will participate in a standard PR program and will receive the oral supplement.

Interventions

Urolithin A (Mitopure)

Compound belonging to the 'urolithin' class. First discovered over 40 years ago as a gut-derived metabolite in rats and subsequently in humans. A food and dietary ingredient, and more specifically, a post-biotic compound. Derived from ellagitannins, which are present in foods such as pomegranate, berries, and walnuts. An 'inducer' of mitophagy.

Placebo

Placebo.

Primary outcome measure

  • Constant Work Rate Exercise Test (CRWET) [ Time Frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks) ]

Central Contacts and Locations

Central contacts

Bryan Ross, MD, FRCPC, MSc (Epi, Physiol)

(514) 843-1465bryan.ross@mcgill.ca

Locations

McGill University Health Centre

Recruiting

Montréal, Quebec, Canada, H4A 3J1

Contacts

Bryan A Ross, MD, FRCPC, MSc (Epi, Physiol)

(514) 843-1465bryan.ross@mcgill.ca

More Information

Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Last update posted

Apr 2, 2024

Last verified

Mar, 2024

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by McGill University Health Centre/Research Institute of the McGill University Health Centre on 2024-04-02.